Recently, severe heart failure patients tend to spend on several months and even years under ventricular assist device (VAD) until transplantation. Therefore, additional therapy such as regeneration therapy that promotes recovery of cardiac function is desired. In this study, we performed gene therapy with Hepatocyte Growth Factor (HGF) that has cardio-protective activities in the impaired goat heart under VAD, and examined the possibility of “bridge to recovery”. Six adult goats (56≈65kg) were created impaired heart by ligating the LAD coronary artery and installed BVAD. The HGF group (n=3) was administered HGF c-DNA-plasmid of 2.0mg directly in myocardium, and the control group (n=3) was administered empty plasmid. Under BVAD, all goats maintained good systemic circulation and LV unloading for four weeks, after that, we tried weaning from VAD. The HGF group showed good hemodynamics while the control group showed its deterioration. The%FS was significantly improved and LV dilatation was markedly suppressed in the HGF group than the control group (HGF vs. control, %FS; 36+/−0.8 vs. 24+/−0.6%, LVDd; 34+/−2 vs. 46+/−2 mm, p<0.05). Vascular density around the infarcted area was markedly increased, and fibrous change was suppressed in the HGF group. These results suggest that gene therapy using HGF may increase the “bridge to recovery” cases in the impaired heart under VAD.